Literature DB >> 34569696

Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.

Jeremy A Syrjanen1, Michelle R Campbell2, Alicia Algeciras-Schimnich2, Prashanthi Vemuri3, Jonathan Graff-Radford4, Mary M Machulda5, Guojun Bu6, David S Knopman4, Clifford R Jack3, Ronald C Petersen1,4, Michelle M Mielke1,4.   

Abstract

INTRODUCTION: Blood-based biomarkers of amyloid pathology and neurodegeneration are entering clinical use. It is critical to understand what factors affect the levels of these markers.
METHODS: Plasma markers (Aβ42, Aβ40, NfL, T-tau, Aβ42/40 ratio) were measured on the Quanterix Simoa HD-1 analyzer for 996 Mayo Clinic Study of Aging (MCSA) participants, aged 51 to 95 years. All other data were collected during in-person MCSA visits or abstracted from the medical record.
RESULTS: Among cognitively unimpaired (CU) participants, all plasma markers correlated with age. Linear regression models revealed multiple relationships. For example, higher Charlson Comorbidity Index and chronic kidney disease were associated with higher levels of all biomarkers. Some relationships differed between mild cognitive impairment and dementia participants. DISCUSSION: Multiple variables affect plasma biomarkers of amyloid pathology and neurodegeneration among CU in the general population. Incorporating this information is critical for accurate interpretation of the biomarker levels and for the development of reference ranges.
© 2021 the Alzheimer's Association.

Entities:  

Keywords:  amyloid; cognition; comorbid conditions; demographics; neurofilament light chain; total tau

Mesh:

Substances:

Year:  2021        PMID: 34569696      PMCID: PMC8957642          DOI: 10.1002/alz.12466

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   16.655


  37 in total

1.  Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Cynthia L Leibson; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

2.  Differences in Obesity Prevalence by Demographic Characteristics and Urbanization Level Among Adults in the United States, 2013-2016.

Authors:  Craig M Hales; Cheryl D Fryar; Margaret D Carroll; David S Freedman; Yutaka Aoki; Cynthia L Ogden
Journal:  JAMA       Date:  2018-06-19       Impact factor: 56.272

Review 3.  Mild cognitive impairment as a diagnostic entity.

Authors:  R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

4.  Comparison of 18F-FDG and PiB PET in cognitive impairment.

Authors:  Val J Lowe; Bradley J Kemp; Clifford R Jack; Matthew Senjem; Stephen Weigand; Maria Shiung; Glenn Smith; David Knopman; Bradley Boeve; Brian Mullan; Ronald C Petersen
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

5.  Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.

Authors:  Rebecca L McNamee; Seong-Hwan Yee; Julie C Price; William E Klunk; Bedda Rosario; Lisa Weissfeld; Scott Ziolko; Michael Berginc; Brian Lopresti; Steven Dekosky; Chester A Mathis
Journal:  J Nucl Med       Date:  2009-02-17       Impact factor: 10.057

6.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Authors:  Clifford R Jack; Val J Lowe; Matthew L Senjem; Stephen D Weigand; Bradley J Kemp; Maria M Shiung; David S Knopman; Bradley F Boeve; William E Klunk; Chester A Mathis; Ronald C Petersen
Journal:  Brain       Date:  2008-02-07       Impact factor: 13.501

7.  Plasma β-amyloid in Alzheimer's disease and vascular disease.

Authors:  Shorena Janelidze; Erik Stomrud; Sebastian Palmqvist; Henrik Zetterberg; Danielle van Westen; Andreas Jeromin; Linan Song; David Hanlon; Cristina A Tan Hehir; David Baker; Kaj Blennow; Oskar Hansson
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

8.  Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates.

Authors:  Alexandros A Polymeris; Michael Coslovksy; Stefanie Aeschbacher; Tim Sinnecker; Pascal Benkert; Richard Kobza; Jürg Beer; Nicolas Rodondi; Urs Fischer; Giorgio Moschovitis; Andreas U Monsch; Anne Springer; Matthias Schwenkglenks; Jens Wuerfel; Gian Marco De Marchis; Philippe A Lyrer; Michael Kühne; Stefan Osswald; David Conen; Jens Kuhle; Leo H Bonati
Journal:  Brain Commun       Date:  2020-10-06

9.  Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis.

Authors:  Steffi De Meyer; Jolien M Schaeverbeke; Inge M W Verberk; Benjamin Gille; Maxim De Schaepdryver; Emma S Luckett; Silvy Gabel; Rose Bruffaerts; Kimberley Mauroo; Elisabeth H Thijssen; Erik Stoops; Hugo M Vanderstichele; Charlotte E Teunissen; Rik Vandenberghe; Koen Poesen
Journal:  Alzheimers Res Ther       Date:  2020-12-05       Impact factor: 6.982

10.  Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.

Authors:  Frank de Wolf; Mohsen Ghanbari; Silvan Licher; Kevin McRae-McKee; Luuk Gras; Gerrit Jan Weverling; Paulien Wermeling; Sanaz Sedaghat; M Kamran Ikram; Reem Waziry; Wouter Koudstaal; Jaco Klap; Stefan Kostense; Albert Hofman; Roy Anderson; Jaap Goudsmit; M Arfan Ikram
Journal:  Brain       Date:  2020-04-01       Impact factor: 13.501

View more
  10 in total

1.  Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years.

Authors:  Joel Simrén; Ulf Andreasson; Johan Gobom; Marc Suarez Calvet; Barbara Borroni; Christopher Gillberg; Lars Nyberg; Roberta Ghidoni; Elisabeth Fernell; Mats Johnson; Herman Depypere; Caroline Hansson; Ingibjörg H Jonsdottir; Henrik Zetterberg; Kaj Blennow
Journal:  Brain Commun       Date:  2022-07-04

2.  Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology.

Authors:  Kacey Berry; Breton M Asken; Joshua D Grab; Brandon Chan; Argentina Lario Lago; Randi Wong; Srilakshmi Seetharaman; Sara C LaHue; Katherine L Possin; Julio C Rojas; Joel H Kramer; Adam L Boxer; Jennifer C Lai; Lawren VandeVrede
Journal:  Alzheimers Dement (Amst)       Date:  2022-07-12

3.  Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective.

Authors:  Michelle M Mielke; Neelum T Aggarwal; Clara Vila-Castelar; Puja Agarwal; Eider M Arenaza-Urquijo; Benjamin Brett; Anna Brugulat-Serrat; Lyndsey E DuBose; Willem S Eikelboom; Jason Flatt; Nancy S Foldi; Sanne Franzen; Paola Gilsanz; Wei Li; Alison J McManus; Debora Melo van Lent; Sadaf Arefi Milani; C Elizabeth Shaaban; Shana D Stites; Erin Sundermann; Vidyani Suryadevara; Jean-Francoise Trani; Arlener D Turner; Jet M J Vonk; Yakeel T Quiroz; Ganesh M Babulal
Journal:  Alzheimers Dement       Date:  2022-04-08       Impact factor: 16.655

4.  Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds.

Authors:  Stuart J McCarter; Timothy G Lesnick; Val J Lowe; Alejandro A Rabinstein; Scott A Przybelski; Alicia Algeciras-Schimnich; Vijay K Ramanan; Clifford R Jack; Ronald C Petersen; David S Knopman; Bradley F Boeve; Kejal Kantarci; Prashanthi Vemuri; Michelle M Mielke; Jonathan Graff-Radford
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

5.  Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community-based sample of 70-year-olds.

Authors:  Anna Dittrich; Nicholas J Ashton; Henrik Zetterberg; Kaj Blennow; Joel Simrén; Fiona Geiger; Anna Zettergren; Sara Shams; Alejandra Machado; Eric Westman; Michael Schöll; Ingmar Skoog; Silke Kern
Journal:  Alzheimers Dement (Amst)       Date:  2022-03-05

6.  Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.

Authors:  Suzanne E Schindler; Thomas K Karikari; Nicholas J Ashton; Rachel L Henson; Kevin E Yarasheski; Tim West; Mathew R Meyer; Kristopher M Kirmess; Yan Li; Benjamin Saef; Krista L Moulder; David Bradford; Anne M Fagan; Brian A Gordon; Tammie L S Benzinger; Joyce Balls-Berry; Randall J Bateman; Chengjie Xiong; Henrik Zetterberg; Kaj Blennow; John C Morris
Journal:  Neurology       Date:  2022-04-21       Impact factor: 11.800

Review 7.  Biomarkers for Alzheimer's Disease: Context of Use, Qualification, and Roadmap for Clinical Implementation.

Authors:  Jeffrey Cummings; Jefferson Kinney
Journal:  Medicina (Kaunas)       Date:  2022-07-19       Impact factor: 2.948

8.  Characterizing Plasma Biomarkers of Alzheimer's in a Diverse Community-Based Cohort: A Cross-Sectional Study of the HAB-HD Cohort.

Authors:  James R Hall; Melissa Petersen; Leigh Johnson; Sid E O'Bryant
Journal:  Front Neurol       Date:  2022-08-18       Impact factor: 4.086

9.  Elevation of plasma phosphorylated tau181 during neurological illnesses affecting consciousness and kidney dysfunction.

Authors:  Poosanu Thanapornsangsuth; Tatchaporn Ongphichetmetha; Watayuth Luechaipanit; Pasin Hemachudha; Thiravat Hemachudha
Journal:  Alzheimers Dement (Amst)       Date:  2022-09-30

10.  Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters.

Authors:  Marco Hermesdorf; David Leppert; Aleksandra Maceski; Pascal Benkert; Jürgen Wellmann; Heinz Wiendl; Jens Kuhle; Klaus Berger
Journal:  Sci Rep       Date:  2022-09-23       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.